Eosinophil peroxidase (EPX) is a marker of eosinophilic inflammation in allergic diseases. Currently, measuring EPX in nasal swabs as a surrogate for airway eosinophil levels is completed using a gold standard enzyme-linked immunosorbent assay (ELISA) lab test. The purpose of…
Eosinophil peroxidase (EPX) is a marker of eosinophilic inflammation in allergic diseases. Currently, measuring EPX in nasal swabs as a surrogate for airway eosinophil levels is completed using a gold standard enzyme-linked immunosorbent assay (ELISA) lab test. The purpose of this project was to develop and validate a novel lateral flow assay (LFA) that measures EPX with the same sensitivity and range of detection as the gold standard EPX ELISA, but that can be efficiently used in clinical settings. The results of this project show that the EPX LFA is a promising method for measuring EPX in nasal swab samples. While future studies are needed for further validation, the EPX LFA could provide rapid point-of-care EPX measurements for clinicians and patients suffering with eosinophil-associated diseases.
Date Created
The date the item was original created (prior to any relationship with the ASU Digital Repositories.)
The purpose of this project was to characterize the mucin layer in patients with eosinophilic esophagitis (EoE). EoE is a chronic disease that is characterized by eosinophilic inflammation in the esophagus. The current diagnosis and standard of care for patients…
The purpose of this project was to characterize the mucin layer in patients with eosinophilic esophagitis (EoE). EoE is a chronic disease that is characterized by eosinophilic inflammation in the esophagus. The current diagnosis and standard of care for patients with EoE is less than ideal. Diagnosis is highly invasive as it requires histological confirmation of eosinophilic inflammation in the esophagus, the patient must undergo an upper endoscopy to obtain the tissue sample. The histology as determined by the pathologist is subjective not quantitative which causes significant error in diagnosis. The current treatment methods are dietary therapy or corticosteroids, which require significant cost and time. The pathology of EoE is largely unknown, though it is known to involve allergic inflammatory and type-2 cytokine-mediated responses. Past studies have determined the genetic expression of mucins to be varied in the esophagi of EoE patients using RNA sequencing techniques. The varied expression of mucins in the esophagi of EoE patients has not been validated at the protein level. This study sought to better define mucin protein expression, specifically that of MUC1, MUC4, and MUC7, in the esophagi of EoE patients (n=4) and control patients (n=3). This was accomplished using histological staining. The tissue samples were stained for eosinophil peroxidase (EPX) in order to visualize the eosinophils, which are a pathological marker of EoE. The results of this study showed a qualitative increase in the protein expression of MUC4 in patients with EoE, indicating that MUC4 may play a protective role in the body’s defense against EoE. MUC1 and MUC7 staining showed no pattern. This study defined the conditions necessary for precise staining of esophageal tissues with the MUC4 8G7 antibody. The orientation of the tissue samples on the slides and the small sample size created significant difficulty in analysis and inhibited quantitative analysis. Future studies with tissue orientation standardization and greater sample size are needed to confirm the findings of this study. If verified, the increase of MUC4 protein expression in patients with EoE has implications for EoE diagnostics and therapeutics.
Date Created
The date the item was original created (prior to any relationship with the ASU Digital Repositories.)